TÀI LIEU TIENG VIÊT:
1. Bô mon bào ché (2005), Ky thuât bào ché và sinh duac hoc câc dang thuôc, Nhà xuât bân Y hoc, trang 175, tâp II.
2. Bô mon bào ché (2005), Mot sô chuyên dé vê bào ché hiên dai, Nhà xuât bân Y hoc, trang 9- 54.
3. Bô mon Duoc lÿ (2006), Duoc ly hoc, truông Dai hoc Duoc Hà Nôi, tâp II, trang 88.
4. Bô mon Hoâ Duoc (2005), Hoâ duoc, truông Dai hoc Duoc Hà Nôi, tâp II, trang 65.
5. Bô y té, Duoc diên Viêt Nam III, Nhà xuât bân y hoc, phu lue 1, 4, 8. 6. Bô y té (2002), Duoc thu quôc gia Viêt nam, trang 747.
7. Bô y té (2003), Thuôc và biêt duoc, Nhà xuât bân y hoc, trang 355, 360, 381,444, 445.
8. Chu Quôc Thinh (2004), Nghiên cüu bào ché viên nang cüng Aspirin khâng dich vi, Khoâ luân tôt nghiêp duoc sÿ dai hoc, truông Dai hoc Duoc Hà Nôi.
9. Phùng Minh Phuong (2006), Nghiên cüu bào ché pellet Omeprazol,
Khoâ luân tôt nghiêp duoc sÿ dai hoc, truông Dai hoc Duoc Hà Nôi. TÀI LIÊU TIÉNG ANH
10. A. Ekpe and T. Jacobsen (1999), Effect of various salts on the stability of lansoprazole, Omeprazole and pantoprazole as determine by high performance liquid chromatography, Drug Dev. Ind. Pharm., 25(9) p.
1057- 1065..
11. A. Farinha et al (2000), Dissolution of Omeprazole from delayed- release solid oral dosage form, Drug Dev. Ind. Pharm, 26(7), p. 785- 790.
12. A. Farinha et al (1999), Bioequivalence évaluation of two Omeprazole enteric- acoated formulations in humans, European Jounal of Pharmaceutical sciences, 7, p. 311- 315.
13. A. Riedel and C. S. Leopold (2005), Dégradation of Omeprazole induced by enteric polymer solutions and aqueous dispersions: HPLC investigations, Drug Dev. Incl. Pharm., 31, p.151- 160.
14. British Pharmacopoeia (2003), (Vol II), p. 1457- 1495.
15. D. Castro et al. (1999), Comparision of derivative spectrophotometric and liquid chromatographic methods for the détermination of omeprazol in aqueous solutions during stability studies, J. Pharm. Biomed. Analys., 21, p.291- 298.
16. European Pharmacopoeia (2002), p. 1675- 1676.
17. Gilbert S. Banker, Christopher Rhodes (1998), Modem Pharmaceutics, Marcel Dekker Inc, p. 227- 229.
18. Herbert A. Lieberman, Léon Lachman, Joseph B. Schwarts (1989),
Pharmaceutical Dosage form, Marcel Dekker Inc, p. 42- 47 19. Indian Pharmacopoeia (1996), Vol I, p. 532- 534.
20. M. J. Arias et al. (2000), Study of Omeprazol- y- cyclodextrin complexation in solid state, Drug Dev. Ind. Pharm, 26(3), p.253- 259.
21. Murât Turkoglu et al (2004), Tableting and stability évaluation of enteric- coated on pellets, European Jounal of Pharmaceutics and Biopharmaceutics, 57, p. 279- 286.
22.The Merck index (2001), An Encyclopedia of chemicals, Drug and Biologicals, Thirteenth édition, Merck and Co, Inc, p. 1224- 1225.
Phu Luc 1
GMP Lab - Scan Report Thu 1 Mar 09:09:39 AM 2007 Batch: Omeprazole
Software version: 01.00(6) Operator: Nguyen Thi Ly
Instrument Parameters Instrument Instrument Version Start (nm) Stop (nm) X Mode Y Mode Baseline Correction Cycle Mode Comments
Sample Name: sample2 Collection Time Peak Table Peak Type Peak Thresnold Range Wavelength (nm) Abs 301.00 0.4427 Cary 100 9.00 350.00 250.00 Nanometers Abs Off Of f Omeprazole/MeOH 3/1/07 8:59:30 AM Maximum Peak 0 . 2 0 0 0 350.00nm to 250.00nm
Phu Luc 2
GMP Lab - Scan Report Thu 1 Mar 09:00:21 AM 2007 Batch: Omeprazole
Software version: 01.00(6) Operator: Nguyen Thi Ly
Instrument Parameters Instrument Instrument Version Start (nm) Stop (nm) X Mode Y Mode Baseline Correction Cycle Mode Comments
Sample Name: samplel Collection Time Cary 100 9. 00 350.00 250.00 Nanometers Abs Off Off Omeprazole/Buffer 6.8 3/1/07 8:50:36 AM Peak Table Peak Type Peak Threshold Range Maximum Peak 0.2000 350.00nm to 250.00nm Wavelength (nm) Abs 300.00 0.5869
Phu lue 3